interleukin-12 adenovirus

Interleukin-12 adenovirus is an engineered, replication-competent, oncolytic adenovirus designed to deliver the interleukin-12 (IL-12) gene directly into tumors[2][3]. The drug utilizes the adenoviral vector (primarily Ad5 serotype) to locally express human IL-12 at the tumor site, thereby stimulating anti-tumor immunity and driving both innate (NK and NKT cells) and adaptive (CD4+, CD8+ T cells) immune responses through Th1 differentiation and increased cytokine production (e.g., IFN-gamma, CXCL10)[2][3]. The strategy allows for high, local IL-12 concentrations, leading to tumor cell killing and antigen release, with reduced systemic toxicity compared to recombinant protein therapies[3]. It may also include suicide genes such as yeast cytidine deaminase (yCD) and mutant HSV-1 thymidine kinase (TKSR39), facilitating cytotoxic gene therapy in combination with immune activation[1][2]. It is primarily under investigation for recurrent prostate cancer and metastatic pancreatic cancer[1][2][3].

Brand names

interleukin-12 adenovirusinterleukin12 adenovirusinterleukin 12 adenovirus

Other names

IL-12 adenoviral vectorIL12 adenoviral vectorIL 12 adenoviral vectoroncolytic IL-12 adenovirusAd-IL-12Ad-IL12Ad-IL 12